Organization | Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.

Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. Report issue

For profit Phase 3 Phase 4

Founded: Suzhou China (2000)

Status: No NME R&D (2000)

Organization Overview

First Clinical Trial

2011

NCT03117335

First Marketed Drug

2011

irinotecan (Camptosar)

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Alternative names

JIANGSU PHARMS | Jiangsu Suzhong Pharmaceutical Group Co., Ltd.

Active Ingredients

Marketed Drugs (13)

carmustine (bicnu) (2021)

caspofungin (cancidas) (2018)

cisatracurium (nimbex) (2017)

cyclophosphamide (cytoxan) (2014)

daptomycin (cubicin) (2019)

dexmedetomidine (precedex) (2017)

docetaxel (taxotere) (2017)

fondaparinux sodium (arixtra) (2018)

gabapentin (neurontin) (2017)

irinotecan (Camptosar) (2011)

letrozole (femara) (2013)

oxaliplatin (eloxatin) (2014)

thiotepa (2018)

Drugs in Phase 4 Trials (2)

abelmoschus manihot (2 trials)

losartan (cozaar) (1 trial)

Drugs in Phase 3 Trials (3)

cisplatin (platinol) (1 trial)

endostatin (endostar) (1 trial)

vinorelbine (navelbine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Glomerulonephritis, IGA (Phase 4)

Kidney Diseases (Phase 4)

Lung Neoplasms (Phase 3)

Renal Insufficiency, Chronic (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial APIs: 5